Clinical Trial Results:
Double-blind, randomized, placebo-controlled, phase II dose-finding study comparing different doses of norursodeoxycholic acid capsules with placebo in the treatment of non-alcoholic fatty liver disease (NAFLD)
Summary
|
|
EudraCT number |
2013-004605-38 |
Trial protocol |
DE AT |
Global end of trial date |
20 Sep 2016
|
Results information
|
|
Results version number |
v1 |
This version publication date |
26 Jan 2019
|
First version publication date |
26 Jan 2019
|
Other versions |
v2 |
Trial Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
Subject Disposition
Baseline Characteristics
End Points
Adverse Events
More Information
|
|||
Trial identification
|
|||
Sponsor protocol code |
NUC-4/NAS
|
||
Additional study identifiers
|
|||
ISRCTN number |
- | ||
US NCT number |
- | ||
WHO universal trial number (UTN) |
- | ||
Sponsors
|
|||
Sponsor organisation name |
Dr. Falk Pharma GmbH
|
||
Sponsor organisation address |
Leinenweberstrasse 5, Freiburg, Germany, 79108
|
||
Public contact |
Dept. of Clin. Res. & Development, Dr. Falk Pharma GmbH, 0049 76115140, zentrale@drfalkpharma.de
|
||
Scientific contact |
Dept. of Clin. Res. & Development, Dr. Falk Pharma GmbH, 0049 76115140, zentrale@drfalkpharma.de
|
||
Paediatric regulatory details
|
|||
Is trial part of an agreed paediatric investigation plan (PIP) |
No
|
||
Does article 45 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Does article 46 of REGULATION (EC) No 1901/2006 apply to this trial? |
No
|
||
Results analysis stage
|
|||
Analysis stage |
Final
|
||
Date of interim/final analysis |
28 Feb 2018
|
||
Is this the analysis of the primary completion data? |
Yes
|
||
Primary completion date |
20 Sep 2016
|
||
Global end of trial reached? |
Yes
|
||
Global end of trial date |
20 Sep 2016
|
||
Was the trial ended prematurely? |
No
|
||
General information about the trial
|
|||
Main objective of the trial |
To evaluate the efficacy of two doses of norursodeoxycholic acid (norUDCA) vs. placebo for the treatment of NAFLD with or without diabetes mellitus type 2
|
||
Protection of trial subjects |
Close supervision of subjects by implementing interim visits every 14 days during the first 4 weeks of treatment and every 4 weeks up to the Follow- Visit at Week 16 to guarantee their safety and wellbeing.
Prior to recruitment of patients all relevant documents of the clinical study were submitted and approved
by the Independent Ethics Committees (IECs) responsible for the participating investigators. Written
consent documents embodied the elements of informed consent as described in the Declaration of
Helsinki, the ICH Guidelines for Good Clinical Practice (GCP) and were in accordance with all applicable
laws and regulations. The informed consent form and patient information sheet described the planned
and permitted uses, transfers and disclosures of the patient's personal data and personal health
information for purposes of conducting the study. The informed consent form and the patient
information sheet further explained the nature of the study, its objectives and potential risks and
benefits as well as the date informed consent was given. Before being enrolled in the clinical trial, every
patient was informed that participation in this trial was voluntary and that he/she could withdraw from
the study at any time without giving a reason and without having to fear any loss in his/her medical
care. The patient’s consent was obtained in writing before the start of the study. By signing the informed
consent, the patient declared that he/she was participating voluntarily and intended to follow the study
protocol instructions and the instructions of the investigator and to answer the questions asked during
the course of the trial.
|
||
Background therapy |
- | ||
Evidence for comparator |
- | ||
Actual start date of recruitment |
30 Mar 2015
|
||
Long term follow-up planned |
No
|
||
Independent data monitoring committee (IDMC) involvement? |
Yes
|
||
Population of trial subjects
|
|||
Number of subjects enrolled per country |
|||
Country: Number of subjects enrolled |
Austria: 37
|
||
Country: Number of subjects enrolled |
Germany: 161
|
||
Worldwide total number of subjects |
198
|
||
EEA total number of subjects |
198
|
||
Number of subjects enrolled per age group |
|||
In utero |
0
|
||
Preterm newborn - gestational age < 37 wk |
0
|
||
Newborns (0-27 days) |
0
|
||
Infants and toddlers (28 days-23 months) |
0
|
||
Children (2-11 years) |
0
|
||
Adolescents (12-17 years) |
0
|
||
Adults (18-64 years) |
186
|
||
From 65 to 84 years |
12
|
||
85 years and over |
0
|
|
|||||||||||||||||||||||||||||
Recruitment
|
|||||||||||||||||||||||||||||
Recruitment details |
A total of 200 patients were enrolled into the study in Austria and Germany from March 2015 to September 2016. | ||||||||||||||||||||||||||||
Pre-assignment
|
|||||||||||||||||||||||||||||
Screening details |
Screening Criteria: 1. Signed Informed Consent 2. Age ≥ 18 years 3. NAFLD 4. ALT >0.8 ULN. In total, 282 patients were screened. Thereof 200 patients were randomised and 198 patients received at least one dose of study medication and were included in the safety set and full analysis set (FAS) . | ||||||||||||||||||||||||||||
Period 1
|
|||||||||||||||||||||||||||||
Period 1 title |
Treatment Phase (overall period)
|
||||||||||||||||||||||||||||
Is this the baseline period? |
Yes | ||||||||||||||||||||||||||||
Allocation method |
Randomised - controlled
|
||||||||||||||||||||||||||||
Blinding used |
Double blind | ||||||||||||||||||||||||||||
Roles blinded |
Subject, Investigator, Monitor, Data analyst, Carer, Assessor | ||||||||||||||||||||||||||||
Arms
|
|||||||||||||||||||||||||||||
Are arms mutually exclusive |
Yes
|
||||||||||||||||||||||||||||
Arm title
|
Arm A | ||||||||||||||||||||||||||||
Arm description |
Norursodeoxycholic acid 1500 mg once daily (6 norUDCA capsules à 250 mg) | ||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||
Investigational medicinal product name |
Norursodeoxycholic acid 1500 mg
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||
Dosage and administration details |
Norursodeoxycholic acid 1500 mg once daily (6 norUDCA capsules à 250 mg)
|
||||||||||||||||||||||||||||
Arm title
|
Arm B | ||||||||||||||||||||||||||||
Arm description |
Norursodeoxycholic acid 500 mg once daily (2 norUDCA capsules à 250 mg and 4 placebo capsules à 250 mg) | ||||||||||||||||||||||||||||
Arm type |
Experimental | ||||||||||||||||||||||||||||
Investigational medicinal product name |
Norursodeoxycholic acid 500 mg
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||
Dosage and administration details |
Norursodeoxycholic acid 500 mg once daily (2 norUDCA capsules à 250 mg and 4 placebo capsules à 250 mg)
|
||||||||||||||||||||||||||||
Arm title
|
Arm C | ||||||||||||||||||||||||||||
Arm description |
6 placebo capsules à 250 mg once daily | ||||||||||||||||||||||||||||
Arm type |
Placebo | ||||||||||||||||||||||||||||
Investigational medicinal product name |
6 placebo capsules à 250 mg
|
||||||||||||||||||||||||||||
Investigational medicinal product code |
|||||||||||||||||||||||||||||
Other name |
|||||||||||||||||||||||||||||
Pharmaceutical forms |
Capsule
|
||||||||||||||||||||||||||||
Routes of administration |
Oral use
|
||||||||||||||||||||||||||||
Dosage and administration details |
6 placebo capsules à 250 mg once daily
|
||||||||||||||||||||||||||||
|
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Baseline characteristics reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Treatment Phase (overall period)
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
- | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
End points reporting groups
|
|||
Reporting group title |
Arm A
|
||
Reporting group description |
Norursodeoxycholic acid 1500 mg once daily (6 norUDCA capsules à 250 mg) | ||
Reporting group title |
Arm B
|
||
Reporting group description |
Norursodeoxycholic acid 500 mg once daily (2 norUDCA capsules à 250 mg and 4 placebo capsules à 250 mg) | ||
Reporting group title |
Arm C
|
||
Reporting group description |
6 placebo capsules à 250 mg once daily |
|
|||||||||||||||||
End point title |
Relative change in ALT | ||||||||||||||||
End point description |
Relative change (%) in ALT between V2 and V6-LOCF
|
||||||||||||||||
End point type |
Primary
|
||||||||||||||||
End point timeframe |
Between V2 (Baseline) and V6-LOCF
|
||||||||||||||||
|
|||||||||||||||||
Statistical analysis title |
normal approximation test for comparing two rates | ||||||||||||||||
Statistical analysis description |
the inverse normal method of combining the p-values of the normal approximation test
for comparing two rates.
|
||||||||||||||||
Comparison groups |
Arm A v Arm B v Arm C
|
||||||||||||||||
Number of subjects included in analysis |
198
|
||||||||||||||||
Analysis specification |
Pre-specified
|
||||||||||||||||
Analysis type |
superiority [1] | ||||||||||||||||
P-value |
< 0.0001 [2] | ||||||||||||||||
Method |
approx.-test for comparing two rates | ||||||||||||||||
Confidence interval |
|||||||||||||||||
Notes [1] - For estimating the treatment effect, the difference between the mean relative ALT change (%) from baseline in the respective treatment group and in the placebo group is provided together with the corresponding two-sided 95% repeated confidence interal (RCI). [2] - Difference between means of Arm A (N1500) and Arm C (Placebo) was -27.8 (overall p-value < 0.0001; 95%-RCI [-34.7,-14.4]). Difference between means of Arm B (N500) and Arm C (Placebo) was -14.6 (overall p-value = 0.0905; 95%-RCI [-20.7, 3.59]). |
|
|||||||||||||||||
End point title |
Number of patients with ALT ≤ 0.8 ULN at V6-LOCF | ||||||||||||||||
End point description |
|||||||||||||||||
End point type |
Secondary
|
||||||||||||||||
End point timeframe |
proportion of patients with ALT ≤ 0.8 ULN at V6-LOCF
|
||||||||||||||||
|
|||||||||||||||||
No statistical analyses for this end point |
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Adverse events information
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Timeframe for reporting adverse events |
Adverse events were assessed at all interim visits (Week 2, 4, 8) to final visit of individual patient or Week 12 respectively. There was a 4-week follow-up after EOT.
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Assessment type |
Systematic | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary used for adverse event reporting
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary name |
MedDRA | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Dictionary version |
19.1
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting groups
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Arm A
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Norursodeoxycholic acid 1500 mg once daily (6 norUDCA capsules à 250 mg) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Arm B
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
Norursodeoxycholic acid 500 mg once daily (2 norUDCA capsules à 250 mg and 4 placebo capsules à 250 mg) | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group title |
Arm C
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Reporting group description |
6 placebo capsules à 250 mg once daily | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Frequency threshold for reporting non-serious adverse events: 5% | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
|
|||
Substantial protocol amendments (globally) |
|||
Were there any global substantial amendments to the protocol? No | |||
Interruptions (globally) |
|||
Were there any global interruptions to the trial? No | |||
Limitations and caveats |
|||
Limitations of the trial such as small numbers of subjects analysed or technical problems leading to unreliable data. | |||
None reported |